skip to main content
Cargill Logo
Cargill
  • Our Stories
  • About Cargill

    About Cargill

    • Thrive Stories
    • Company Overview
    • Executive Team
    • 2022 Annual Report
    • Our History
    • Community Engagement
    • Research & Development
    • Diversity, Equity and Inclusion
    • Workplace Safety
    • Ethics & Compliance
    • Supplier Central
    • Contact Us
  • Sustainability

    Sustainability

    • Supply Chains
    • Sustainability Priorities
    • 2022 ESG Report
    • Reporting Hub
    • Newsletter signup
    • Innovation that Sustains
  • Products & Services

    Products & Services

    • Agriculture
    • Animal Nutrition
    • Beauty
    • Bioindustrial
    • Foodservice
    • Food & Beverage
    • Industrial
    • Pharmaceutical
    • Meat & Poultry
    • Risk Management
    • Supplements
    • Transportation
  • News

    News

    • All Press Releases
    • Company Statements
    • In The News
  • Careers
  • Worldwide
  • Contact
Home/Products & Services/Supplements/EpiCor® Postbiotic/Spring Trial Abstract
  • Supplements
    • EpiCor® Postbiotic
      • Contact Us
      • Download EpiCor® Resources
      • FAQs
      • Sales & Distribution
 

Spring Trial Abstract

Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals.

Moyad, M. A., et al. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther 2009, 26 (8), 795-804. [Online reference: https://www.ncbi.nlm.nih.gov/pubmed/19672568]

Introduction: Allergic rhinitis (AR) impacts around 25% of the worldwide population. However, cost, safety, and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion. Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound; therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms.

Methods: A 12-week, randomized, double-blind, placebo-controlled clinical trial of 96 healthy subjects with a recent clinically documented history of seasonal allergies and AR was conducted. Participants received once-daily supplementation with 500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product (EpiCor, Embria Health Sciences, Ankeny, Iowa, USA) or placebo during the 12-week period of the highest recorded concentrations of total pollen counts for this Midwest geographic area. Clinical outcome measurements included in-clinic examinations, validated questionnaire and standard diary, and serologic analysis at baseline, 6 and 12 weeks.

Results: During the highest pollen count period (weeks 1-6), EpiCor significantly reduced the mean severity of specific AR symptoms, including a significant reduction in nasal congestion (P=0.04), rhinorrhea (P=0.005), and a nonsignificant reduction in ocular discharge symptoms. A significantly (P=0.04) reduced total number of days with nasal congestion (12.5 fewer days) favored EpiCor compared with placebo, as did the nasal congestion section of the quality of life questionnaire (P=0.04). Subjects receiving the intervention also experienced significantly (P=0.03) higher salivary IgA levels. Adverse events were similar to placebo.

 

EpiCor Research Study - Effects on Seasonal Allergies

 

Download Report

Conclusion: This yeast-derived product appeared to be safe and efficacious and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion.

   

 

 

 

Some Cargill products are only approved for use in certain geographies, end uses, and/or at certain usage levels. It is the customer's responsibility to determine, for a particular geography, that (i) the Cargill product, its use and usage levels, (ii) the customer's product and its use, and (iii) any claims made about the customer's product, all comply with applicable laws and regulations.

Twitter Facebook Linkedin YouTube Instagram
Contact Worldwide
Privacy Notices Fraud Notice
Website Terms of Use Purchase Order Terms
© 2023 Cargill, Incorporated. All Rights Reserved.